Indication
Positron Emission Tomography
7 clinical trials
6 products
1 drug
Clinical trial
Fibroblast Activation Protein PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors ApplicationStatus: , Estimated PCD: 2023-07-28
Clinical trial
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in CombinationStatus: Completed, Estimated PCD: 2021-10-19
Product
⁸⁹Zr-Df-IAB22M2CClinical trial
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive DiseaseStatus: Recruiting, Estimated PCD: 2025-04-30
Product
68Ga-PSFAClinical trial
68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational StudiesStatus: Recruiting, Estimated PCD: 2025-05-01
Product
68Ga-FAP-CHXClinical trial
68Ga-PSMA-11 PET/CT in Patients With Various Types of CancerStatus: Recruiting, Estimated PCD: 2024-12-30
Drug
68Ga-PSMA-11Clinical trial
68Ga-DOTA/NOTA-FAPI PET/CT in Patients With Various Fibrotic DiseaseStatus: Recruiting, Estimated PCD: 2024-04-01
Product
68Ga-FAPI-04Clinical trial
68Ga-NOTA Evans Blue PET/CT in Patients With Lymphatic System Related DiseasesStatus: Recruiting, Estimated PCD: 2024-12-30
Product
68Ga-NOTA Evans Blue